Mørup Sara Bohnstedt, Leung Preston, Reilly Cavan, Sherman Brad T, Chang Weizhong, Milojevic Maja, Milinkovic Ana, Liappis Angelike, Borgwardt Line, Petoumenos Kathy, Paredes Roger, Mistry Shweta S, MacPherson Cameron R, Lundgren Jens, Helleberg Marie, Reekie Joanne, Murray Daniel D
Centre of Excellence for Health, Immunity, and Infections, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Division of Biostatistics and Health Data Science, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
AIDS Res Ther. 2024 May 3;21(1):27. doi: 10.1186/s12981-024-00610-x.
Human genetic contribution to HIV progression remains inadequately explained. The type 1 interferon (IFN) pathway is important for host control of HIV and variation in type 1 IFN genes may contribute to disease progression. This study assessed the impact of variations at the gene and pathway level of type 1 IFN on HIV-1 viral load (VL).
Two cohorts of antiretroviral (ART) naïve participants living with HIV (PLWH) with either early (START) or advanced infection (FIRST) were analysed separately. Type 1 IFN genes (n = 17) and receptor subunits (IFNAR1, IFNAR2) were examined for both cumulated type 1 IFN pathway analysis and individual gene analysis. SKAT-O was applied to detect associations between the genotype and HIV-1 study entry viral load (log10 transformed) as a proxy for set point VL; P-values were corrected using Bonferroni (P < 0.0025).
The analyses among those with early infection included 2429 individuals from five continents. The median study entry HIV VL was 14,623 (IQR 3460-45100) copies/mL. Across 673 SNPs within 19 type 1 IFN genes, no significant association with study entry VL was detected. Conversely, examining individual genes in START showed a borderline significant association between IFNW1, and study entry VL (P = 0.0025). This significance remained after separate adjustments for age, CD4 T-cell count, CD4/CD8 T-cell ratio and recent infection. When controlling for population structure using linear mixed effects models (LME), in addition to principal components used in the main model, this was no longer significant (p = 0.0244). In subgroup analyses stratified by geographical region, the association between IFNW1 and study entry VL was only observed among African participants, although, the association was not significant when controlling for population structure using LME. Of the 17 SNPs within the IFNW1 region, only rs79876898 (A > G) was associated with study entry VL (p = 0.0020, beta = 0.32; G associated with higher study entry VL than A) in single SNP association analyses. The findings were not reproduced in FIRST participants.
Across 19 type 1 IFN genes, only IFNW1 was associated with HIV-1 study entry VL in a cohort of ART-naïve individuals in early stages of their infection, however, this was no longer significant in sensitivity analyses that controlled for population structures using LME.
人类基因对HIV进展的影响仍未得到充分解释。1型干扰素(IFN)途径对宿主控制HIV很重要,1型IFN基因的变异可能导致疾病进展。本研究评估了1型IFN基因和途径水平的变异对HIV-1病毒载量(VL)的影响。
分别分析了两组未接受抗逆转录病毒治疗(ART)的HIV感染者(PLWH)队列,一组为早期感染(START),另一组为晚期感染(FIRST)。检测了17个1型IFN基因和受体亚基(IFNAR1、IFNAR2),用于累积1型IFN途径分析和单个基因分析。应用SKAT-O检测基因型与HIV-1研究入组时病毒载量(log10转换)之间的关联,以此作为设定点VL的替代指标;P值使用Bonferroni法校正(P<0.0(025))。
早期感染组的分析包括来自五大洲的2429名个体。研究入组时HIV VL的中位数为14,623(IQR 3460-45100)拷贝/mL。在19个1型IFN基因中的673个单核苷酸多态性(SNP)中,未检测到与研究入组时VL的显著关联。相反,在START组中对单个基因进行检测时,发现IFNW1与研究入组时VL之间存在临界显著关联(P=0.0025)。在分别对年龄、CD4 T细胞计数、CD4/CD8 T细胞比值和近期感染进行调整后,这种显著性仍然存在。当使用线性混合效应模型(LME)控制群体结构时,除了主模型中使用的主成分外,这种关联不再显著(P=0.0244)。在按地理区域分层的亚组分析中,仅在非洲参与者中观察到IFNW1与研究入组时VL之间的关联,不过,使用LME控制群体结构时,这种关联并不显著。在IFNW1区域内的17个SNP中,在单SNP关联分析中,只有rs79876898(A>G)与研究入组时VL相关(P=0.0020,β=0.32;G与高于A的研究入组时VL相关)。这些发现未在FIRST组参与者中得到重现。
在19个1型IFN基因中,只有IFNW1与感染早期未接受ART治疗的个体队列中的HIV-1研究入组时VL相关,但在使用LME控制群体结构的敏感性分析中,这种关联不再显著。